FREE patent keyword monitoring and additional FREE benefits. http://images1.freshpatents.com/images/triangleright (1K) REGISTER now for FREE triangleleft (1K)
FreshPatents.com Logo    FreshPatents.com icons
Monitor Keywords Patent Organizer File a Provisional Patent Browse Inventors Browse Industry Browse Agents


Drug, Bio-affecting And Body Treating Compositions > Immunoglobulin, Antiserum, Antibody, Or Antibody Fragment, Except Conjugate Or Complex Of The Same With Nonimmunoglobulin Material > Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)

Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.)

Structurally-modified Antibody, Immunoglobulin, Or Fragment Thereof (e.g., Chimeric, Humanized, Cdr-grafted, Mutated, Etc.) patent applications listed include Date, Patent Application Number, Patent Title, Patent Abstract summary and are linked to the corresponding patent application page.

10/16/14 - 20140308269 - Humanized antibodies
Humanized antibodies that bind ICAM-1 are provided. Antibodies include those selected from: SEQ ID NO:1 and 3 (HumA); SEQ ID NO:5 and 7 (HumB); SEQ ID NO:9 and 11 (HumC); SEQ ID NO:13 and 15 (HumD); SEQ ID NO:17 and 19 (HumE); SEQ ID NO:21 and 23 (HumF); SEQ ID...

10/16/14 - 20140308270 - Method and formulation for reducing aggregation of a macromolecule under physiological conditions
The invention provides a method for reducing aggregation and inhibiting flocculation of a macromolecule, such as a protein, under physiological conditions, by the addition of 5% to 20% polyvinylpyrrolidone (PVP) with a molecular weight range of 2000 to 54,000 daltons. The invention further provides a method to minimize inflammation at...

10/16/14 - 20140308271 - Antibodies that bind to tl1a and their uses
The present invention relates to antibodies or fragments thereof that bind to TL1A. More specifically, the present invention relates to an antibody or fragment thereof that binds to TL1A comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 51, and/or a heavy chain CDR2 comprising...

10/16/14 - 20140308272 - Treatment of prion protein related diseases
According to the present invention, treatment of prion protein related diseases, and in particular cancer tumours, is effected by providing to a subject in need thereof a therapeutically effective amount of an agent capable of modulating binding of a prion protein and/or a prion-like protein to a disease related GAG...

10/16/14 - 20140308273 - Cell culture media and methods of antibody production
Cell culture media are provided herein as are methods of using the media for cell culture and antibody production from cells. Compositions comprising antibodies and fragments thereof, produced by the methods herein are also provided....

10/16/14 - 20140308274 - Combination cancer treatments utilizing synthetic oligonucleotides and egfr-tki inhibitors
The disclosure provides methods and compositions for treating cancer cells, including cancer cells in a subject, whereby two or more therapeutic agents are used, one being an EGFR-TKI agent and the other being a synthetic oligonucleotide....

10/16/14 - 20140308275 - Methods for diagnosing and treating myhre syndrome
The present invention relates to methods for diagnosing and treating Myhre Syndrome. The invention provides a method for diagnosing or predicting Myhre Syndrome, or a risk of Myhre Syndrome, in a subject, which method comprises detecting a mutation in SMAD4 gene, as compared to a control population, wherein the presence...

10/16/14 - 20140308276 - Anti-ox40 antibodies and methods of using the same
Human antibodies, preferably recombinant human antibodies, both humanized and chimeric, which specifically bind to human OX40 are disclosed. Preferred antibodies have high affinity for OX40 receptor and activate the receptor in vitro and in vivo. The antibody can be a full-length antibody or an antigen-binding portion thereof. The antibodies, or...

10/16/14 - 20140308277 - Pertuzumab variants and evaluation thereof
The present application discloses variants of Pertuzumab. In particular, it discloses: an unpaired cysteine variant comprising Cys23/Cys88 unpaired cysteines in one or both variable light domains of Pertuzumab, an afucosylated variant of Pertuzumab, a low-molecular-weight-species (LMWS) of Pertuzumab, and a high-molecular-weight-species (HMWS) or Pertuzumab. The application further discloses the isolated...

10/16/14 - 20140308278 - Class i anti-cea antibodies and uses thereof
The present invention provides compositions and methods of use of humanized, chimeric or human Class I anti-CEA antibodies or fragments thereof, preferably comprising the light chain variable region CDR sequences SASSRVSYIH (SEQ ID NO:1); GTSTLAS (SEQ ID NO:2); and QQWSYNPPT (SEQ ID NO:3); and the heavy chain variable region CDR...

10/16/14 - 20140308279 - Anti-erbb3 antibodies and uses thereof
The present invention provides antibodies that bind to ErbB3 and methods of using same. According to certain embodiments of the invention, the antibodies are fully human antibodies that bind to human ErbB3. In certain embodiments, the antibodies of the present invention block the interaction of ErbB3 with an ErbB3 ligand...

10/09/14 - 20140302009 - Medicinal agent for prevention or treatment of diseases associated with intraocular neovascularization and/or intraocular vascular hyperpermeability
in the formula, R1 and R2 are simultaneously or individually each a hydrogen atom, a halogen atom, a trifluoromethyl group, a lower alkyl group, a lower alkoxy group or a nitro group, and R3 is a hydrogen atom, a halogen atom or a lower alkyl group, or a pharmacologically acceptable...

10/09/14 - 20140302010 - Substituted benzimidazoles
The present invention relates to substituted benzimidazole compounds of general formula (I) in which R3, R5 and A are as defined in the claims, to methods of preparing said compounds, to pharmaceutical compositions and combinations comprising said compounds and to the use of said compounds for manufacturing a pharmaceutical composition...

10/09/14 - 20140302011 - Compositions including triciribine and trastuzumab and methods of use thereof
This application relates to combination therapies including triciribine and related compounds and trastuzumab or a salt thereof and compositions with reduced toxicity for the treatment and prevention of tumors, cancer, and other disorders associated with abnormal cell proliferation....

10/09/14 - 20140302012 - Combination therapies for treating hematologic malignancies using pyridopyrimidinone inhibitors of pi3k/mtor with bendamustine and/or rituximab
The invention provides a method for treating cancers including hematologic malignancies comprising administering a compound of Formula (I): in combination with one or both of bendamustine and rituximab....

10/09/14 - 20140302013 - Predicting and diagnosing patients with systemic lupus erythematosus
The present invention provides methods for the prediction and diagnosis of Systemic Lupus Erythematosus using single nucleotide polymorphisms in IRF8....

10/09/14 - 20140302014 - Methods for the treatment of cancer using coenzyme q10 combination therapies
Presented herein are methods for the treatment of oncological disorders by the co-administration of CoQ10 formulations and chemotherapeutic agents and/or surgery. The CoQ10 formulations may be at least one of intravenous, topical, or by inhalation. The chemotherapeutic agents may be at least one of antimetabolites or anthracyclines. Co-administration of the...

10/09/14 - 20140302015 - Antibodies against human il33r and uses thereof
An antibody binding to IL33R characterized in that the heavy chain variable domain comprises a CDR3 region of SEQ ID NO:1, a CDR2 region of SEQ ID NO:2 and a CDR1 region of SEQ ID NO:3 and in that the light chain variable domain comprises a CDR3 region of SEQ...

10/09/14 - 20140302016 - Binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind cd154 and uses thereof
This invention provides binding proteins, including antibodies, antibody derivatives and antibody fragments, that specifically bind a CD154 (CD40L) protein. This invention also provides a chimeric, humanized or fully human antibody, antibody derivative or antibody fragment that specifically binds to an epitope to which a humanized Fab fragment comprising a variable...

10/09/14 - 20140302017 - Treating skin cancer
This document provides methods and materials related to treating skin cancer. For example, methods and materials relating to the use of a taxane compound, an alkylating agent, and an anti-VEGF polypeptide antibody to treat skin cancer are provided....

10/09/14 - 20140302018 - Treatment of diffuse large-cell lymphoma with anti-cd20 antibody
The present invention concerns methods for the treatment of diffuse large cell lymphoma by administration of an anti-CD20 antibody and chemotherapy. Particular embodiments include the administration of anti-CD20 antibody in combination with chemotherapy comprising CHOP (cyclophosphamide, hydroxydaunorubicin/doxorubicin, vincristine, and prednisone/prednisolone) and/or in combination with a transplantation regimen....

10/09/14 - 20140302019 - Blood plasma biomarkers for bevacizumab combination therapies for treatment of pancreatic cancer
The present invention provides methods for improving the treatment effect of a chemotherapy regimen of a patient suffering from pancreatic cancer, in particular metastatic pancreatic cancer by adding bevacizumab (Avastin®) to a chemotherapy regimen by determining the expression level, in particular the blood plasma expression level, of one or more...

10/09/14 - 20140302020 - Anti-clusterin antibodies and antigen binding fragments and their use to reduce tumor volume
Novel antibodies and antigen binding fragments that specifically bind to clusterin are described. In some embodiments, the antibodies block the biological activity of clusterin and are useful in composition in certain cancers, more particularly in cancers, such as endometrial carcinoma, breast carcinoma, hepatocellular carcinoma, prostate carcinoma, a renal cell carcinoma,...

10/09/14 - 20140302021 - Antibody formulations and methods
Antibody formulations and methods useful for prophylaxis or treatment of amyloidosis, including AA amyloidosis and AL amyloidosis....

10/09/14 - 20140302022 - 2-carboxamide clycloamino urea derivatives for use in treating vegf-dependent diseases
in the treatment of warm-blooded animal target of VEGF-driven angiogenic diseases, methods of use of said compounds in the treatment of said diseases in a warm-blooded animal, especially a human, pharmaceutical compositions comprising said compounds for the treatment of said diseases and said compounds for use in the treatment of...

10/09/14 - 20140302023 - Use of rank/rankl antagonists for treating neuromuscular disorders, genetic myopathies and/or non genetic myopathies and/or for regulating skeletal and cardiac muscle disuse, diseases and aging
A pharmaceutical composition includes one or more RANK/RANKL antagonists and a pharmaceutically acceptable carrier. The composition can be used for treating neuromuscular disorders, non-genetic myopathies, or genetic myopathies; maintaining and/or preserving the excitation:contraction:relaxation coupling; reducing loss of muscle strength associated with neuromuscular disorders, non-genetic myopathies or genetic myopathies; reducing the...

10/02/14 - 20140294805 - Novel compounds and compositions for the inhibition of nampt
The present invention relates to compounds and compositions for the inhibition of NAMPT, their synthesis, applications and antidotes. An illustrative compound of the invention is shown below:...

10/02/14 - 20140294806 - Methods and compositions for treating cancers having acquired resitance to prior chemotherapeutic and targeted drugs using carboxyamidotriazole orotate
This invention provides methods and compositions useful for treating early and late stage metastatic cancer to prevent or treat acquired resistance due to gene amplification or mutation in response to chemotherapeutic and/or targeted drugs. In particular, the methods and compositions include carboxiamidotriazole orotate (CTO) alone or in combination with specific...

10/02/14 - 20140294807 - Combination therapy with type i and type ii anti-cd20 antibodies
The present invention is directed to a combination therapy involving a type I anti-CD20 antibody and a type II anti-CD20 antibody for the treatment of a patient suffering from cancer, particularly a CD20-expressing cancer. An aspect of the invention is a composition comprising a type I anti-CD20 antibody and a...

10/02/14 - 20140294808 - Treating cancer with hsp90 inhibitory compounds
Methods of treating cancer with a compound of formulae (I) or (Ia) are disclosed. Also provided are methods of treating a cancer with a mutation in ALK or a c-MET mutation with a compound of formulae (I) or (Ia). Further provided are methods of treating non-small cell lung cancer with...

10/02/14 - 20140294809 - Anti-alpha(v)beta(6) antibodies and uses thereof
The present invention is in the fields of cell biology, immunology and oncology. The invention provides humanized antibodies that recognize αvβ6 integrins, which antibodies comprise a variable region of nonhuman origin and at least a portion of an immunoglobulin of human origin. The invention also provides methods for preparation of...

10/02/14 - 20140294810 - Immunoglobulin variants and uses thereof
Variant immunoglobulins with one or more amino acid modifications in the Fc region that have increased in vivo half-lives, and methods of using the same are provided....

10/02/14 - 20140294811 - Method for predicting risk of hypertension associated with anti-angiogenesis therapy
The invention is concerned with a method of predicting a patient's susceptibility to developing hypertension associated with an anti-angiogenesis treatment, such as bevacizumab, by determining the genotype of KDR gene and/or EGF gene. The invention further relates to a pharmaceutical composition comprising an angiogenesis inhibitor, such as bevacizumab, for the...

10/02/14 - 20140294812 - Fc variants that improve fcrn binding and/or increase antibody half-life
The present invention discloses the generation of novel variants of Fc domains, including those found in antibodies, Fc fusions, and immuno-adhesions, which have an increased binding to the FcRn receptor and/or increased serum half-life....

10/02/14 - 20140294813 - Tnf binding proteins
Provided are TNF binding proteins and methods of treatment using the same. Also provided are nucleic acids encoding the binding proteins and recombinant expression vectors and host cells for making such binding proteins....

10/02/14 - 20140294814 - Humanized and affinity-matured anti-c-met antibody and uses thereof
Provided is a humanized and affinity-matured anti-c-Met antibody, a pharmaceutical composition including the antibody, and a method of preventing and/or treating c-Met-related disease using the antibody....

10/02/14 - 20140294815 - Caninised tumour necrosis factor antibodies and methods of using the same
Caninised and chimeric antibodies and antigen binding fragments thereof which bind specifically to canine tumour necrosis factor and inhibit the ability of canine TNF to bind to the TNFR1 receptor are provided. The invention further extends to nucleic acids encoding same and to methods of treating chronic inflammatory disease such...

10/02/14 - 20140294816 - Combination therapy for the treatment of ocular neovascular disorders
The invention features methods for treating a patient diagnosed with, or at risk of developing, a neovascular disorder by administering a PDGF antagonist and a VEGF antagonist to the patient. The invention also features a pharmaceutical composition containing a PDGF antagonist and a VEGF antagonist for the treatment or prevention...

10/02/14 - 20140294817 - Polypeptides comprising fc fragments of immunoglobulin g (igg) and methods of using the same
Polypeptides comprising at least a first and second Fc fragment of IgG that can be used to induce a stimulated cell to produce the anti-inflammatory cytokine Interleukin-10 and methods of using the same are disclosed herein....

10/02/14 - 20140294818 - Pgam1 inhibitors and methods related thereto
In certain embodiments, the disclosure relates to methods of treating or preventing a PGAM1 mediated condition such as cancer or tumor growth comprising administering an effective amount of PGAM1 inhibitor, for example, an anthracene-9,10-dione derivative to a subject in need thereof. In certain embodiments, the disclosure relates to methods of...

10/02/14 - 20140294819 - Canine/feline cd20 binding epitope and compositions for binding thereto
The present invention provides acyclic polypeptide fragment of CD20 comprising (i) a contiguous amino acid sequence consisting of amino acid residues SEKNS (SEQ ID NO:67); (ii) a first cysteine residue which is present at a region N-terminal to the contiguous amino acid sequence and (iii) a second cysteine residue which...

09/25/14 - - Stable igg4 based binding agent formulations
The present invention provides stable pharmaceutical antibody formulations, including liquid drug product formulations and lyophilized drug product formulations, comprising an IgG4 binding agent and a citrate buffer, wherein the pH of the formulation is at or below both pH 6 and the pI of the binding agent. The formulations can...

09/25/14 - 20140286934 - Humanized antibodies that bind to cd19 and their uses
The present invention relates to humanized antibodies or fragments thereof that bind to human CD19. More specifically, the present invention relates to a humanized antibody or fragment thereof that binds to human CD19 comprising a heavy chain CDR1 comprising the amino acid sequence of SEQ ID NO: 27, and/or a...

09/25/14 - 20140286935 - Antigen binding proteins
This application discloses antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells....

09/25/14 - 20140286936 - Anti-human cxcr4 antibodies
The present invention provides novel antibodies to human CXCR4 with high affinity to the target and the ability to act potently as antagonists. The antibodies disclosed herein bind to a diverse range of epitopes....

09/25/14 - 20140286937 - Antibodies binding to an intracellular prl-1 or prl-3 polypeptide
We provide an antibody capable of binding to an intracellular PRL-I or PRL-3 polypeptide, in which the antibody is capable of binding to an epitope bound by antibody 269, antibody 223 or antibody 318. Such anti-PRL antibodies may be capable of binding to intracellular PRL-I or PRL-3. They may be...

09/25/14 - 20140286938 - Spiroketals
The present invention relates to spiroketal compounds that are useful in methods of treating or preventing protozoal infections, parasitic infections, bacterial infections, cell proliferative disorders and anti inflammatory disorders. The spiroketal compounds are also useful as immunosuppressive agents, and also in methods of controlling pests....

09/25/14 - 20140286939 - Treatment of tnfalpha related disorders
Methods of treating TNFα-related disorders comprising administering TNFα inhibitors, including TNFα antibodies are described....

09/25/14 - 20140286940 - Treatment of tnfalpha related disorders
Methods of treating TNFα-related disorders comprising administering TNFα inhibitors, including TNFα antibodies are described....

09/25/14 - 20140286941 - Treatment of tnfalpha related disorders
Methods of treating TNFα-related disorders comprising administering TNFα inhibitors, including TNFα antibodies are described....

09/25/14 - 20140286942 - Methods for treating chronic obstructive pulmonary disease
The present invention provides methods of treating a mammal having chronic obstructive pulmonary disease (COPD), independent of both smoking status and asthma status, with a therapeutically effective amount of an anti-IgE moiety. In accordance with the invention, COPD patients with an elevated serum IgE level may benefit from the treatment...

09/25/14 - 20140286943 - Cyclopropyl modulators of p2y12 receptor
The present invention relates to new cyclopropyl modulators of P2Y12 receptor activity, pharmaceutical compositions thereof, and methods of use thereof....

09/25/14 - 20140286944 - Methods of treating cardiovascular diseases and predicting the efficacy of exercise therapy
Methods of treating a subject having a cardiovascular disease, selecting a therapy for a subject having a cardiovascular disease, identifying a subject having a cardiovascular disease that will benefit or not benefit from exercise therapy, determining whether a subject having a cardiovascular disease should begin, continue, not begin, discontinue, or...

09/25/14 - 20140286945 - Enzyme inhibitor for cancer treatment
Disclosed herein is a new and improved therapy for the treatment of diseases including cancer, which comprises the step of altering cell membrane lipid composition by treating a cancer cell with an enzyme inhibitor which inhibits enzymes regulating the cholesterol biosynthetic pathway. The method may also be employed in combination...

09/25/14 - 20140286946 - Method for preparing antibodies having improved properties
The present invention is directed to methods and compositions for the production of Fc-containing polypeptides having improved properties....